Protein Labeling

Protein labeling using transglutaminase (TGase) is a smart enzymatic labeling alternative to chemical protein labeling procedures.

Protein biotinylation, PEGylation or site-directed protein labeling with fluorescent dyes are common applications of TGase labeling.

Zedira’s protein labeling tools are available as
  • TGase Protein Labeling Kits
  • Individual components
  • TGase Labeling Service
TGase Protein Labeling Kits Zedira

Advantages of transglutaminase (TGase) mediated site-specific protein labeling: 

  • Defined degree of labeling
  • Defined label position(s)
  • Homogenously labeled protein
  • Higher solubility in water
  • Minimized amounts of unlabeled protein
  • No or reduced impact on bioactivites of labeled proteins
Principle of TGase-catalyzed protein labeling, protein modification and protein conjugation

TGases catalyse the acyl transfer reaction between the γ-carboxyamide group of protein-bound glutamine residues and the ε-amino group of protein-bound lysine or primary amines. Thus, primary amines as well as glutamine-containing peptides may carry a broad variety of labels like biotin, PEG or fluorescent dyes etc.
TGase labeling principle

Requirements for transglutaminase labeling

Transglutaminase protein labeling requires substrate sequences on the target protein surface, which are in general not abundant on proteins:
  • Accessible lysine residues
  • or accessible glutamine residues
  • otherwise transglutaminase substrate sequence tags can be introduced recombinantly, if no lysine or glutamin residues are accessible

Examples for utilization of modified proteins

  • Fluorescence-based HTS-assay
  • Diagnostics (antibodies, antibody-bindingproteins, lectins etc.)
  • Therapeutic proteins (PEGylation)
  • Protein immobilization (after biotinylation)

Please find information about TGase Protein Labeling Kits, the individual components and Zedira’s TGase Labeling Service in the respective categories.

In case of any questions just contact us!

Phone:      +49 6151 3251-00


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA